Skip to main content

Table 1 Baseline features of the study cohort (n = 226)

From: Discordance between patient and physician global assessment of disease activity in Behçet’s syndrome: a multicenter study cohort

Males, n (%) 111 (49.1%)
Age at enrolment, median (IQR) years 46.9 (35.6–55.2)
Disease duration, median (IQR) years 11.7 (5.9–20.8)
Comorbidities, n (%) 99 (43.8%)
Active disease manifestations
 Mucocutaneous lesions, n (%) 83 (36.7%)
 Ocular involvement, n (%) 12 (5.3%)
 Arthritis, n (%) 17 (7.5%)
 Major organ involvement, n (%) 20 (8.8%)
Disease activity indices
 PGA, median (IQR) score 1.0 (0.0–3.0)
 PtGA, median (IQR) score 2.0 (0.3–5.0)
 BDCAF, median (IQR) score 3.0 (0.0–5.0)
Irreversible organ damage
 BODI, median (IQR) score 1.0 (0.0–2.0)
HR-QoL (by SF-26)
 PCS, median (IQR) score 46.6 (38.8–54.2)
 MCS, median (IQR) score 44.9 (35.9–54.4)
Current and past therapy
 Colchicine, n (%) 107 (47.3%)
 Glucocorticoids, n (%) 104 (45.6%)
 Immunosuppressants, n (%) 95 (42.0%)
 Biologics, n (%) 49 (21.7%)
  1. IQR interquartile range, BDCAF Behçet’s Disease Current Activity Form, PGA physician global assessment, PtGA patient global assessment of disease activity, BODI Behçet’s syndrome Overall Damage Index, HR-QoL health-related quality of life, PCS physical component summary in the SF-36 questionnaire, MCS mental component summary in the SF-36 questionnaire